Essure Study Criticized

NBC News, November 4, 2013. Dr. Diana Zuckerman, who leads the National Research Center for Women and Families, a non-partisan FDA watchdog, said the survey questionnaires exhibit dubious research methods. “These studies are always done by the company that is selling the product so it is not exactly unbiased,” Zuckerman said. Continue reading

Lawsuits pile up over popular birth control pill

Chicago Tribune. September 15, 2013. Birth control pills containing drospirenone “shouldn’t be on the market because there are so many safer alternatives,” said Diana Zuckerman, president of the National Research Center for Women & Families. “We can debate how unsafe it is and for whom — more research could obviously clarify that — but there’s really no doubt that it’s not as safe as dozens of other birth control pills.” Continue reading

Letter to the editor: Still working to understand cancer

The Post article on the overdiagnosis of cancer clearly reported the need to reduce patients’ fear and confusion about “cancers” that many experts now agree are not really cancer, because they don’t spread and aren’t harmful. The major obstacle has been uncertainty about how likely these conditions are to predict cancer or change into an invasive cancer in the future. Continue reading

FDA Kicks Off Women’s Health Program With Surgical Mesh Registry

FDA’s launch of a new registry for controversial surgical transvaginal mesh products as part of a new program focusing on women’s health could signal the agency is planning to prioritize sex-specific device concerns, a consumer advocate said. “If they start with new patients, it will take years before we get the information that we need,” said Diana Zuckerman, president of the National Research Center for Women & Families. Continue reading

The Op-Ed: FDA Panels: Too Many Conflicts Or Too Little Expertise?

June 2013. Should FDA Advisory Committee members be allowed to have financial conflicts of interest regarding the approval of medical products? Diana Zuckerman discusses how financial ties to pharmaceutical companies can influence the voting and discussion on drug and medical device approvals, and how misunderstandings of statistics and the value of clinical trials can lead to the approval of dangerous products. Continue reading

TN Compounder’s Steroid Sickens Patients

TN Compounder’s Steroid Sickens Patients – May 25, 2013 – “Nobody imagined that a company with the reassuringly named ‘Main Street Pharmacy’ could be shipping contaminated medical products to patients in 13 states,” said Diana Zuckerman, president of the National Research Center for Women and Families. “Unfortunately, the public is at just as much risk now as we were when patients first started dying from contaminated medicines last year.” Continue reading